Q2 2024 Evolent Health Inc Earnings Call Transcript
Key Points
- Evolent Health Inc (EVH) delivered revenue just above the anticipated range for the second quarter, with profitability within the expected range.
- The company secured new rate increases from Performance Suite customers, expected to contribute approximately $60 million in additional annual revenue.
- Evolent Health Inc (EVH) announced four new revenue agreements in the second quarter, adding over $70 million in new annualized revenue bookings.
- The company completed several successful large-scale implementations, including a national rollout of their oncology solution.
- Evolent Health Inc (EVH) has a strong cash position of $101 million, even after significant outflows for acquisitions.
- The adjusted EBITDA for the quarter was towards the lower part of the range, totaling $52 million.
- The company experienced higher than expected medical costs in some markets due to elevated disease prevalence and acuity.
- Revenue from the Specialty Technology and Services segment decreased by $7.5 million sequentially.
- The timing of revenue recognition for the Medicare Shared Savings Program was a headwind, impacting comparisons to the prior quarter.
- Evolent Health Inc (EVH) had to narrow its scope in certain markets, which will modestly reduce full-year revenue.
Welcome to the Evolent earnings conference call for the second quarter Ended June 30, 2024. As a reminder, this conference call is being recorded.
Your hosts for the call today from Evolent are Seth Blackley, Chief Executive Officer and John Johnson, Chief Financial Officer. This call will be archived and available later this evening and for the next week via the webcast on the Company's website in the section titled Investor Relations.
I will now hand the call to Seth Frank, Evolent's Vice President of Investor Relations.
Thank you, and good evening. This conference call will contain forward-looking statements under the U. S. Federal laws. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations.
A description of some of the risks and uncertainties can be found in the Company's reports that are filed with the Securities and Exchange Commission, including
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
